Canonic’s second generation products are characterized by high levels of THC, the primary psychoactive ingredient in cannabis, at 23% and above; the highest THC percentage allowed in Israel being 24.4%. The six new products released into the market in Israel are named: Synergy (THC 24%), Combo (THC 24%), Mosaic (THC 23%), Two Stars (THC 24.2%), Mash Kush (THC 24.4%) and Blend Kush (THC 23.8%).

The new products were developed through breeding programs carried out by Canonic in parallel to the release in 2021 of Canonic’s first-generation two products: G200 (THC 19%) & G150 (THC 18%). The second-generation products were developed using proprietary sets of novel genetic markers developed in collaboration with Evogene, using its GeneRator AI tech-engine, specifically looking for a higher level of THCs and particular terpene characteristics. The use of novel genetic markers directed and accelerated the breeding process towards the unique cannabis lines with desired characteristics, based on market feedback. This made the entire product development process faster and more accurate in achieving the right characteristics in the designed variety.

Eyal Ronen, Chief Executive Officer of Canonic, commented, “Utilizing Canonic’s and Evogene’s advanced technologies for selecting novel genetic markers, allowed us to accelerate & direct the development of our advanced cannabis varieties. We are very proud to have completed the launch of six new products in the Israeli market, and we expect sales growth in 2023. Looking ahead, we will continue the development of our third-generation products, particularly with selecting new and unique terpenes. Furthermore, we intend to sell our products to broader markets starting with Europe.”

About Canonic Ltd.:

Canonic is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), developing medical cannabis products utilizing Evogene’s proprietary GeneRator AI engine. The Company’s development products aim to improve active compounds, genetic stability, and cannabis varieties for specific medical effects. In addition, the Company’s strategy includes the development of cannabis varieties to commercialize medical cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical cannabis products.

About Evogene Ltd.:

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI, and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating a deep multidisciplinary understanding of life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and strategic partners. Evogene’s main subsidiaries currently utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by AgPlenus Ltd., and ag-biologicals by Lavie Bio Ltd.

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, “demonstrates”, or words of similar meaning. For example, Evogene and Canonic are using forward-looking statements in this press release when they discuss the sales growth in 2023, development of third-generation products, sale to broader markets including Europe. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

LOS ANGELES, May 20, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has licensed its brand to Larsen Group II LLC, a Colorado manufacturer of cannabis products. Larsen Group II LLC will produce and distribute formulas such as Irwin Naturals Power to Sleep with THC.

Irwin’s CEO, Klee Irwin, said, “I’m pleased with how quickly our team is lining up distribution across the US in what is now already our 3^rd state in about a month. Larsen Group II LLC was selected because of their growth-focused mindset and operational excellence. Important, they have one of the broadest distribution bases in the state – a state with $2.2 billion in cannabis sales last year¹.

Mr. Irwin continued, “Licensing is a win-win approach for three reasons. (1) It provides significant tax advantages to us, (2) it greatly reduces our need for cash investment to set up factories and distribution systems in each state and (3), most importantly, it allows us to carpet the countries with dispensaries selling Irwin Naturals formulas infused with THC in a remarkably short period of time as we embark on this landgrab to become the world’s first household name brand in cannabis. Our partners in CA, CO and NM are now able to distribute a brand known by over 100 million North Americans**, with high trust ratings and a loyal customer base.”

Zac Larsen, owner of Larsen Group II LLC, commented, “Like all the other states, Colorado doesn’t have a household brand in cannabis yet. This is about to change with the entrance of Irwin Naturals into our market. Of course, this same brand has actually been in our state in virtually every health food store and mass market chain store for over 25 years. Accordingly, we are proud to have been selected by Klee and the team to help bring this suite of widely recognized products to our state.”

______________________________

¹ Source: https://mjbizdaily.com/colorados-2021-cannabis-sales-set-another-annual-record-at-2-22-billion/

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years*. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand**. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

*Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.

**Based on a formal Company survey with a sample size of 500 randomly selected adults.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

SCOTTSDALE, AZ / ACCESSWIRE / September 22, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is set to launch over 40 products on the Alibaba Platform with one product already available through this link provided. https://www.alibaba.com/product-detail/LBC-Hemp-Oil-Herbal-Drops-500mg_10000003855426.html?spm=a2747.manage.0.0.1fef2c3cPWZsnK.

CBD Life Sciences Inc. is excited to start blasting products onto the platform with over 40 different options! The products the company is working with to upload are Tinctures, Edibles, Skincare, Pet Products, CBD Cartridges, etc. President & CEO Lisa Nelson states “This is huge news for us, and we are going to start out with 41 products for now as we are rapidly growing, and this is only the beginning.” Lisa Nelson also states, “Multiple streams of revenue is the goal here and we are already off to a phenomenal start with Amazon & now Alibaba!” CBD Life Sciences Inc. is currently planning to add more products to Amazon along with getting on as many platforms as possible to push the products out the door and connect with multiple businesses around the world.

Alibaba is comfortably one of the most popular sites among the world’s largest Internet market. As of Q2 2014, the site boasted around 279 million annual active buyers, and it’s been suggested that by the year 2017, more than $700 billion of combined sales could be made through its various websites and marketplaces including Taobao, Tmall and Alipay. Alibaba also has a huge global appeal. You can find, buy from, and sell to companies and users in over 240 countries around the world. This gives you unprecedented scope to open global markets, however small your business. Can you imagine how much time and money you’d need to invest on overseas travel, promotion, and trade shows to open those markets up on your own? Overall, B2B e-commerce is the way to go in 2021 and CBD Life Sciences Inc. is ahead of the game by far.

B2B e-commerce refers to the exchange of goods and services between businesses via online platforms. While the use of digital channels has previously been limited to B2C companies, consumer brands, and retail transactions, there have also been major digital advances and unprecedented adoption of e-commerce solutions in the B2B landscape over the past few years. In 2019, the global B2B e-commerce gross merchandise volume (GMV) amounted to 12.2 trillion U.S. dollars, up from approximately 5.83 trillion U.S. dollars in 2013. This rapid growth of the global B2B e-commerce space not only mirrors the ongoing digitalization of commerce, but it also signals the systematic digital restructuring of the B2B market worldwide. Lastly, according to Forrester, U.S. business-to-business (B2B) ecommerce transactions are expected to reach $1.8 trillion by 2023. This would account for 17% of all B2B sales in the country.

CBD Life Sciences Inc. is getting close to its 3^rd retail location along with a recreational marijuana facility. This will be significant as far as expansion and revenue go and CBD Life Sciences Inc. will keep the public informed moving forward.

The number of benefits CBD has is tremendous! These benefits include help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson’s, osteoporosis, and ALS. CBD can also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn’s, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

LBC BIOSCIENCE INC. ONLINE STORE

LBC BIOSCIENCE’S Online Emporium

LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings – all at very reasonable prices. Check out LBC Bioscience Inc’s newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.

Become a Distributor

• Large Selection of Products (over 50 items and growing)
• 100% USA Made Products “organic & kosher.”
• All Products are THC-FREE (they contain 0.00% THC)
• Weekly Deals (new deals every week)
• 25% off on all products using code “LBC25.”

LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc’s Main Website at www.lbcbioscienceinc.com

Amazon: https://www.amazon.com/shops/lbcbioscienceinc

About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC’s products can be viewed and purchased on the Company’s website at www.lbcbioscienceinc.com.

Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: [email protected]
Website: www.tenassociatesllc.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc’s, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

SOURCE: CBD Life Sciences Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.